Ad copy

A European dermatology review challenged the bacterial model of acne For decades, acne was treated as a bacterial disorder. Reduce bacteria. Dry the skin. Suppress sebum. That framework shaped standard acne care for years. As part of the review, researchers analyzed outcomes from patients with persistent acne undergoing standard topical treatments over six months. Bacterial counts decreased. Sebum production was reduced. Yet inflammatory lesions continued to recur. “We assumed bacteria were the starting point,” explains one of the review’s contributing authors. “But imaging and biomarker analysis showed inflammation was already active long before any visible breakout.” Using advanced dermal analysis, researchers detected elevated inflammatory signaling—particularly IL-1α expression and NF-κB activation—weeks before pores clogged or bacterial overgrowth appeared. In other words, acne wasn’t beginning at the surface. It was being triggered at the signaling level. This finding helped explain a long-standing paradox in dermatology: Why antibacterial and drying treatments often produce short-term improvement, yet fail to prevent recurrence. They act after the inflammatory cascade is already underway. In parallel, a group of researchers in Norway began exploring a different hypothesis. Instead of targeting bacteria or sebum, they focused on regulating the early inflammatory signals that initiate acne. By isolating specific bioactive compounds from arctic plant species, they developed topical molecules capable of modulating inflammatory pathways at the skin level—before visible lesions form. Early clinical use showed: • reduced inflammatory markers • fewer recurrent breakouts • improved long-term control without systemic exposure. Today, this approach is quietly being adopted across European clinics as an alternative to aggressive pharmaceutical treatments. Some dermatologists are already calling it: “the beginning of the end for reactive acne care.” →